Kyorin Pharmaceutical Co., Ltd.
https://www.kyorin-pharm.co.jp/en/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kyorin Pharmaceutical Co., Ltd.
Proposed US BIOSECURE Act - Do Lonza, Other CDMOs Gain And How Soon?
Concerns over the impact of the proposed US BIOSECURE Act on the CRO and CDMO segments linger despite proponent Mike Gallagher’s plan to leave Congress soon. Which global manufacturers could gain, what determines a shift away from Chinese companies and how imminent is this? Scrip brings insights from industry feedback and other sources.
Finance Watch: The Biggest Biopharma IPO Of 2024 May Not Happen In The US
Public Company Edition: Galderma proposed pricing for its $2.6bn Swiss public market debut. Also, Apogee and Akero lead follow-on offerings with $483m and $366.9m, respectively, and Lexicon’s private placement brings in $250m, while Spruce reveals a 21% workforce reduction.
WuXi AppTec Quits BIO As Group Endorses BIOSECURE Act
BIO chairman Ted Love had said at BIO CEO last month that “damaging” the company could have unintended consequences.
Ionis Could Be A Factor In MASH With Positive Phase II Data
Ionis’s DGAT2 inhibitor showed potential to improve disease activity score and resolve metabolic-associated steatohepatitis in a Phase II study, but analysts point to fibrosis-reduction data as competitively intriguing.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- Nutraceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- ActivX Biosciences, Inc., KYORIN Holdings, Inc., Kyorin Rimedio
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice